METASTATIC COLORECTAL CANCER

This trial investigates whether adding a dietary supplement called sodium nucleinate to standard FOLFOX chemotherapy helps people with metastatic colorectal cancer (cancer that has spread). Participants are randomly assigned to receive either the supplement or a placebo alongside…

This study tested whether adding the arthritis drug Celebrex to an experimental chemo drug called EPO906 could reduce severe diarrhea in people with advanced colorectal cancer. The trial enrolled 75 patients who had already tried other treatments. The first phase found the safest…

This study tested whether adding bevacizumab to a powerful four-drug chemotherapy regimen (FOLFOXIRI) could shrink liver tumors in people with colorectal cancer that had spread only to the liver and could not be removed surgically. The goal was to see if more patients could then …

This early-stage study tested a new antibody drug (similar to cetuximab) in 18 people with advanced colorectal cancer that had stopped responding to standard treatments. The main goal was to check safety and how the drug moves through the body. Participants received one of two do…

This study tested whether a new drug called A140 works as well as the standard drug Erbitux for people with a certain type of advanced colorectal cancer (RAS wild-type). Both drugs were given together with chemotherapy. The trial involved 688 adults and measured how many patients…

This study looked at the long-term safety of the cancer drug vismodegib in 19 patients with ovarian cancer, basal cell carcinoma, or metastatic colorectal cancer. All participants had previously taken vismodegib in an earlier Genentech trial and were expected to benefit from cont…

This study tested an experimental drug called CTX-009 in 49 adults with metastatic colorectal cancer that had worsened after two or three prior treatments. The goal was to see if the drug could shrink tumors or stop them from growing. Results will help determine if further testin…

This study tested a new two-drug combination (encorafenib and cetuximab) against standard treatments in 107 Chinese patients with a specific genetic mutation (BRAF V600E) that makes colorectal cancer harder to treat. The goal was to see if the new combo could slow cancer growth b…

This study tested a new cancer drug called ERAS-007, given by mouth, together with other targeted therapies in 101 people with advanced colorectal or pancreatic cancers that have certain gene changes. The main goals were to check safety, find the best dose, and see how the drugs …

This study tested a combination of two drugs, palbociclib and cetuximab, in 24 people with a specific type of advanced colon cancer that had spread. The goal was to see if the combo could shrink tumors or stop them from growing. Participants took palbociclib pills and received ce…

This study tested a two-step approach for people with metastatic colorectal cancer that doesn't respond well to standard treatments. First, patients received a drug called temozolomide to make their tumors more genetically unstable. Then, they received the immunotherapy drug pemb…

This study tested a combination of two treatments (regorafenib and FOLFIRINOX) in 13 people with a type of advanced colorectal cancer that has a specific gene change (RAS mutation). The main goal was to see if the combination was safe and tolerable. The study also looked at how l…

This early-phase study tested a combination of two drugs, regorafenib and nivolumab, in 52 people with advanced colorectal cancer that had stopped responding to other treatments. The goal was to find the safest dose and see if the combination could help control the cancer. The st…

This study tested a combination of two drugs, sorafenib and irinotecan, in 64 adults with metastatic colorectal cancer that has a K-RAS mutation and has progressed after prior treatment. The goal was to see if the combination could control the disease and to check for side effect…

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This study tested a new antibody called ICT01 combined with low-dose interleukin-2 (IL-2) in 56 people with advanced solid tumors like colorectal, ovarian, and pancreatic cancer. The goal was to see if the combo is safe and can shrink tumors. Early results suggest it may help con…

This study tested whether adding the immunotherapy drug pembrolizumab to standard radiation or ablation could help people with metastatic colorectal cancer. The idea is that the combination might trigger a stronger immune response that also attacks tumors not directly treated. Th…

This completed Phase IIB trial tested an experimental immunotherapy called STIMVAX (AlloStim) in 29 adults with metastatic colorectal cancer that had not responded to two prior chemotherapy regimens. The treatment uses immune cells from healthy donors to try to fight the cancer. …

This study tested combinations of a new drug called etrumadenant (AB928) with other treatments in 227 people whose colorectal cancer had spread. The goal was to see if these combinations could shrink tumors or slow the cancer's growth. Participants received different drug mixes, …

This study tested whether adding the targeted drug panitumumab to standard chemotherapy (given through the liver artery and a vein) could help keep colorectal cancer from returning after liver metastases were surgically removed. It involved 75 adults with a specific gene type (wi…

This small, early-phase trial tested a combination of two drugs—cetuximab and capecitabine—as a maintenance treatment for people with a specific genetic type of advanced colorectal cancer (KRAS/BRAF wild-type). The main goals were to check safety, find the best dose, and see how …

This completed trial tested a web-based remote monitoring platform called CONTINUUM+ CONNECT in 411 adults with metastatic breast, lung, colorectal, or prostate cancer. Patients used the platform to report symptoms and receive alerts, aiming to improve their physical health and q…

This study tested whether taking zinc supplements and applying a strong steroid cream (clobetasol) can prevent or reduce hand-foot skin reaction, a common and painful side effect of the cancer drug regorafenib. About 150 patients starting regorafenib were split into three groups:…

This study looked at whether a new blood test called EPISPOT can predict how well chemotherapy works in people with metastatic colorectal cancer. Researchers measured circulating tumor cells in 168 patients before and during treatment. The goal was to see if early changes in thes…

This study looked at 74 people with metastatic colorectal cancer starting their first chemotherapy. Researchers took blood samples early in treatment to measure three markers: CEA, circulating tumor DNA, and total cell-free DNA. The goal was to see if early changes in these marke…

This study followed 704 adults with metastatic colorectal cancer who received regorafenib through a French compassionate-use program. Researchers measured how long patients lived after starting the drug and collected data on tumor characteristics and prior treatments. The goal wa…

This study looks at data from 121 people with metastatic colorectal cancer who received two approved treatments—regorafenib and TAS (with or without bevacizumab)—in different orders. Researchers want to see which sequence works better and how long patients live. Since this is an …

This study looked at how bevacizumab, a drug used to treat advanced colorectal cancer, affects the stiffness of arteries. Researchers measured artery stiffness in 13 patients before and after 4 months of treatment. The goal was to better understand the drug's cardiovascular side …

This study looked back at medical records of 274 people with a specific type of advanced colorectal cancer (BRAF V600E mutation) to see what treatments they received and how well they worked. The goal was to understand real-world treatment patterns and outcomes, since there is no…

This study tested whether special sensors could measure changes in urine chemicals to track how chemotherapy affects cancer growth. Researchers collected daily urine samples from 16 people with metastatic colorectal cancer before and after starting chemotherapy. The goal was to s…

This study tested whether special sensors could measure certain molecules in urine to track how cancer treatment is working. Researchers collected urine samples from 32 people with metastatic colorectal cancer and healthy volunteers over two days. The goal was to see if these mol…